Webinar
Optimizing DLBCL Patient Outcomes with clonoSEQ MRD Monitoring
Date: September 29, 2025 | 2:00 PM
For patients with DLBCL, minimal residual disease (MRD) testing can mean more than just numbers on a report — it can help guide therapy choices, inform surveillance, and give patients clarity about what comes next.
In this session, Tara Graff, DO, MS (Mission Cancer + Blood) and Jay Patel, PharmD, BCOP (Adaptive Biotechnologies) will share how MRD monitoring fits into real-world care: when to use it, how to interpret results, and how to talk about them with patients in a way that builds trust and understanding.
What You’ll Learn:
- A clear view of why MRD monitoring matters in DLBCL
- Practical examples of how to use clonoSEQ to track therapy response and long-term outcomes
- Communication strategies that help patients feel supported, not overwhelmed, by their results
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
Upcoming Webinar
Updates in Breast Cancer: Antibody-Drug Conjugates and Cyclin-Dependent Kinase Inhibitors
June 15, 2026 | 2:00 PM
June 16, 2026 | 2:00 PM